Investor Relations

Stock Information


Nasdaq: VTGN




52 week Low/High

Day Low/High

Company Overview

VistaGen Therapeutics (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medicines that go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen's three CNS drug candidates, PH94B, PH10, and AV-101, has a differentiated mechanism of action, a favorable safety profile in all clinical studies to date, and therapeutic potential in multiple CNS markets.

Contact Information

VistaGen Therapeutics, Inc.
Mark McPartland
Vice President, Corporate Development
+1(650) 577-3606

VistaGen Therapeutics
Mark Flather
Vice President, Investor Relations
+1(650) 577-3617

Transfer Agent
Computershare, Inc.
P.O. BOX 30170
College Station, TX 77842
(800) 368-5948